SUBSCRIBE
SUBSCRIBE
News   FDA

Novartis Corporation’s MS Drug Gets Approval in EU

May 27, 2008 | 
1 min read
ZURICH, May 26 (Reuters) - Swiss drugmaker Novartis said on Monday its Extavia multiple sclerosis drug had been approved in the European Union and repeated that it planned to launch Extavia in the U.S. and Europe in the first half of 2009.
FDA Approvals Europe
MORE ON THIS TOPIC
Target concept vector illustration. Business goal, marketing strategy, digital aim, bullseye accuracy, cyber challenge, innovation target, focus objective, dart board, internet market.
Phase 3
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
August 13, 2026
 · 
3 min read
 · 
Gabrielle Masson
Insights
The Italian inflection point: Clinical strength, culture and capital
August 13, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
 · 
3 min read
 · 
Annalee Armstrong
FDA
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
August 12, 2026
 · 
1 min read
 · 
Jef Akst